Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears AdvanDx Test for Gram-negative Bloodstream Infection

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AdvanDx announced today that its GNR Traffic Light PNA FISH test has received 510(k) clearance from the US Food and Drug Administration.

The test is the first capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from blood cultures containing Gram-negative rods in less than 90 minutes, the molecular diagnostics firm said.

According to the company, which has offices in Woburn, Mass., and Vedbaek, Denmark, the GNR Traffic Light PNA FISH test identifies E. coli, K. pneumoniae and P. aeruginosa from positive blood cultures one to two days earlier than with traditional methods, allowing physicians to start appropriate treatment more quickly.

In a statement, the company said that Gram-negative blood stream infections are considered among the most serious hospital-acquired infections, affecting more than 100,000 patients in the US each year. Of these infections, about 70 percent to 80 percent are caused by E. coli, K. pneumoniae and P. aeruginosa and increased resistance to antibiotics and the time it takes to get test results with traditional testing methods — two to three days — make it challenging to treat the infections.

As a result, up to 33 percent of patients with Gram-negative blood stream infections initially receive inappropriate antibiotic therapy, leading to higher mortality rates of up to 40 percent, longer hospital stays, and significant extra costs, AdvanDx said.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.